Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 6/20 | 0.67 |
| ▸ | F7 | P08709 | 1/20 | 0.52 |
| ▸ | F3 | P13726 | 1/20 | 0.52 |
| ▸ | PYGL | P06737 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | GABRP | O00591 | 2/20 | 0.48 |
| ▸ | GABRD | O14764 | 2/20 | 0.48 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.48 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.48 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.48 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.48 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.48 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.48 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.48 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.48 |
| ▸ | GABRE | P78334 | 2/20 | 0.48 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21437660 | 0.91 | NR4A2 (0.67) | NR4A2PYGLMEN1MAPTKMT2A | |
| SCHEMBL21438565 | 0.86 | NR4A2 (0.67) | NR4A2MEN1MAPTKMT2AAHR | |
| SCHEMBL21438639 | 0.86 | NR4A2 (0.67) | NR4A2MEN1MAPTKMT2AGABRA1 | |
| SCHEMBL21366224 | 0.84 | MEN1 (0.68) | NR4A2MEN1MAPTKMT2AAHR | |
| SCHEMBL22462609 | 0.82 | MEN1 (0.72) | NR4A2F7F3PYGLMEN1 | |
| SCHEMBL4242189 | 0.81 | NR4A2 (1.00) | NR4A2F7F3PYGLGABRP | |
| SCHEMBL21438336 | 0.79 | NR4A2 (0.70) | NR4A2MEN1MAPTKMT2AAHR | |
| SCHEMBL21438856 | 0.79 | NR4A2 (0.70) | NR4A2MEN1MAPTKMT2AAHR | |
| SCHEMBL20258217 | 0.75 | NR4A2 (0.81) | NR4A2F7F3PYGLGABRP | |
| SCHEMBL21437542 | 0.75 | MAP2K1 (0.69) | NR4A2MEN1MAPTKMT2AAHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3774767-B1 | ARYL HYDROCARBON RECEPTOR MODULATORS AND USES THEREOF | BETH ISRAEL DEACONESS MEDICAL CT INC (US) | 2025-10-29 | — | — | EP | disclosed |
| US-12152016-B2 | Aryl hydrocarbon receptor modulators and uses thereof | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2024-11-26 | — | — | US | disclosed |
| US-20230278986-A1 | ARYL HYDROCARBON RECEPTOR MODULATORS AND USES THEREOF | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230278986-A1 | ARYL HYDROCARBON RECEPTOR MODULATORS AND USES THEREOF | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230278986-A1 | ARYL HYDROCARBON RECEPTOR MODULATORS AND USES THEREOF | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-11634408-B2 | Aryl hydrocarbon receptor modulators and uses thereof | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2023-04-25 | — | — | US | disclosed |
| US-20210147390-A1 | ARYL HYDROCARBON RECEPTOR MODULATORS AND USES THEREOF | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2021-05-20 | — | — | US | disclosed |
| US-20210147390-A1 | ARYL HYDROCARBON RECEPTOR MODULATORS AND USES THEREOF | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2021-05-20 | — | — | US | disclosed |
| EP-3774767-A1 | ARYL HYDROCARBON RECEPTOR MODULATORS AND USES THEREOF | Beth Israel Deaconess Medical Center, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| WO-2019195682-A1 | ARYL HYDROCARBON RECEPTOR MODULATORS AND USES THEREOF | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2019-10-10 | — | — | WO | disclosed |
| WO-2019195682-A1 | ARYL HYDROCARBON RECEPTOR MODULATORS AND USES THEREOF | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2019-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147390-A1 | ARYL HYDROCARBON RECEPTOR MODULATORS AND USES THEREOF | AHR, ARNT, NR4A1 | NR4A2 11/4885F7 4142/4885F3 1438/4885 |
| US-11634408-B2 | Aryl hydrocarbon receptor modulators and uses thereof | AHR, ARNT, NR4A1 | NR4A2 11/4885F7 4142/4885F3 1438/4885 |
| US-20230278986-A1 | ARYL HYDROCARBON RECEPTOR MODULATORS AND USES THEREOF | AHR, ARNT, NR4A1 | NR4A2 14/4885F7 4104/4885F3 1417/4885 |
| US-12152016-B2 | Aryl hydrocarbon receptor modulators and uses thereof | AHR, ARNT, NR4A1 | NR4A2 11/4885F7 4142/4885F3 1438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.